Gilead's Expanded Access Shift Offers New Data Collection Opportunities For Remdesivir

Pivot from individual- to multi-patient protocols for expanded access may help generate data to inform regulatory filings and even payer determinations for Gilead’s potential COVID-19 treatment.

Gilead Sciences Inc.’s transition from single to multi-patient expanded access protocols for its experimental antiviral remdesivir will offer the company the opportunity for enhanced data collection that could be used to bolster regulatory filings or even reimbursement discussions, experts say.

Remdesivir is currently in late-stage clinical trials for COVID-19. The company announced Saturday it was transitioning to multi-patient expanded...